Arrow Ventures has committed up to USD $4.85 million to Nutrivert to support US trials of a non-antibiotic livestock treatment. The funding will back studies involving 4,800 pigs in the US Midwest.
Nutrivert is testing its LDPP product against four comparator groups: pigs receiving LDPP, antibiotics, both treatments, or neither. The studies aim to measure weight gain, feed conversion efficiency and overall mortality under commercial production conditions.
The Singapore-based investor was founded by Australian veterinary pharmaceuticals entrepreneur Nick Bova. It is also seeking up to USD $125 million in direct investment for its venture fund, which focuses on small biotechnology companies developing veterinary medicines.
LDPP is being developed as an immune stimulant for livestock. Nutrivert says it is intended to strengthen resistance to disease, reduce inflammation and support growth, while offering producers an alternative to antibiotics used in animal production.
For decades, antibiotics have been used in livestock production to promote growth and improve feed efficiency, although many countries have restricted their use for this purpose. Reducing unnecessary antibiotic use is also part of broader efforts to limit antimicrobial resistance, which affects the effectiveness of antibiotics used to treat infections in humans.
The current US studies are a significant step for Nutrivert because they are designed to test whether LDPP can match or improve the feed conversion outcomes associated with antibiotics. Feed conversion measures how much feed is needed to produce a given amount of animal weight gain and is a key cost factor in swine production.
Peter Selover, Chief Financial Officer and Co-Founder of Nutrivert, said the trials were assessing weight gain and feed conversion efficiency.
Source link







